Atezo-Bev Shows Real-World Efficacy in Unresectable HCC Outcomes of a retrospective study of atezolizumab plus bevacizumab for unresectable HCC were similar to those of the IMbrave150 study.

#Atezolizumab plus #Bevacizumab (atezo-bev) has shown favorable efficacy and manageable toxicity in patients with unresectable #HepatocellularCarcinoma (HCC). Study in Biomedicines.

Read here: https://bit.ly/3MRWJDW

#RareDisease #AtezoBev #HCC #Oncology